GSK buoyed by GAVI support of new vaccines
The Global Alliance for Vaccines and Immunisation (GAVI) has committed funds to purchase GSK's new vaccines against rotavirus and pneumococcal diseases.
The Global Alliance for Vaccines and Immunisation (GAVI) has committed funds to purchase GSK's new vaccines against rotavirus and pneumococcal diseases.
Rotavirus and pneumococcal disease are some of the biggest threats to children in the developing world. GSK's rotavirus vaccine is now registered in more than 75 countries and its vaccine candidate for pneumococcal disease is now in late stage clinical development.
GSK said: "We are pleased to partner with GAVI to make these new vaccines available at affordable prices. The GAVI eligible countries will benefit from our tiered pricing model which has been used for more than 20 years to ensure vaccines reach all those who need them."
GAVI is a public-private partnership focused on increasing children's access to vaccines in poor countries. Partners include the GAVI Fund, national governments, UNICEF, WHO, The World Bank, the Bill & Melinda Gates Foundation, the vaccine industry, public health institutions and nongovernmental organisations (NGOs).